Find clinical trials for Pancreatic Cancer in Indianapolis, IN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Colorectal Cancer
Lung Cancer
Non-Small-Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck

Pancreatic Cancer trials near Indianapolis, IN, USA:

Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer (LAPIS)

with either gemcitabine plus nab-paclitaxel (G/NP) or FOLFIRINOX in the treatment of participants with locally advanced, unresectable pancreatic...

Active, not recruiting
Pancreatic Cancer Non-resectable
Drug: Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
Drug: Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX

Phase 3


Indianapolis, Indiana, United States and 89 other locations

A) vs. mFOLFIRINOX plus placebo (Arm B) in 94 subjects with advanced pancreatic cancer, not amenable to curative treatment. Both ar...

Active, not recruiting
Pancreatic Cancer
Drug: Ramucirumab

Phase 2

Walid Shaib, MD

Indianapolis, Indiana, United States and 7 other locations

This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumor...

Exocrine Pancreatic Cancer
Carcinoma, Non-Small-Cell Lung
Drug: cisplatin
Drug: carboplatin

Phase 2


Indianapolis, Indiana, United States and 63 other locations

The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors an...

Active, not recruiting
Esophageal Cancer
Urologic Cancer
Drug: Niraparib

Phase 2

Tempus AI
Tempus AI

Indianapolis, Indiana, United States and 79 other locations

This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, phar...

NF1 Mutation
Advanced Solid Tumor
Drug: ABM-168

Phase 1

ABM Therapeutics

Indianapolis, Indiana, United States and 5 other locations

consist of Part 1 which includes 7 cohorts of: urothelial bladder cancer, biliary tract cancer, cervical cancer, endometri ...

Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer
Drug: Trastuzumab deruxtecan

Phase 2


Muncie, Indiana, United States and 113 other locations

irinotecan (nal-IRI) with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-nal-IRI) for treatment of patients with locally advanced pancreatic...

Active, not recruiting
Locally Advanced Pancreatic Carcinoma(LAPC)
Drug: FOLFOX regimen
Drug: Liposomal Irinotecan

Phase 2

Nelson Yee

Indianapolis, Indiana, United States and 3 other locations

The study will determine the recommended Phase 2 dose (RP2D) of livmoniplimab (ABBV-151) administered as monotherapy and in combination with budigali...

Advanced Solid Tumors Cancer
Drug: Livmoniplimab
Drug: Budigalimab

Phase 1


Indianapolis, Indiana, United States and 38 other locations

The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or re...

Advanced MTAP-null Solid Tumors
Drug: Docetaxel
Drug: AMG 193

Phase 1, Phase 2


Indianapolis, Indiana, United States and 52 other locations

This is a Phase 1b/2, multi-center, open label umbrella study of patients ≥12 years of age with recurrent, progressive, or refractory melanoma or oth...

Non Small Cell Lung Cancer
Bladder Cancer
Drug: Pimasertib
Drug: Tovorafenib

Phase 1, Phase 2

Day One Biopharmaceuticals

Indianapolis, Indiana, United States and 20 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems